Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Waiting for the fda news COMING today on $IGXT
For $IGXT longs....http://www.marketwatch.com/story/intelge...
100 SHARES?
new high?
I think your high on something.
Be for real
Not enough liquidity in $ACTN to raise the bid.
Beware of the company!
Trust me
Tell me something is not about to go down at >>> $CDII <<<
Insider Transaction: $CDII Purchase at $0.90per share of 20000 shares by Director Shen Philip Y on 2011-09-22.
yahoo Thu, Sep 22, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.90 per share of 20000 shares by Director Steiner Sheldon on 2011-09-21.
yahoo Thu, Sep 22, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.85 per share of 14000 shares by Director Wasserman Adam on 2011-09-23.
yahoo Fri, Sep 23, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.87 per share of 150000 shares by Officer Wang Yuejian on 2011-09-22.
yahoo Fri, Sep 23, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.85 per share of 14000 shares by Director Wasserman Adam on 2011-09-23.
yahoo Fri, Sep 23, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.86 per share of 15000 shares by Officer Wang Andrew X. on 2011-09-26.
yahoo Mon, Sep 26, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.96 per share of 95200 shares by Director Tung Kong on 2011-09-29.
yahoo Thu, Sep 29, 2011, 04:44 PM EST
Insider Transaction: $CDII Purchase at $0.86 per share of 53575 shares by Officer Huang Yuwei on 2011-09-28.
yahoo Thu, Sep 29, 2011, 04:44 PM EST
Insider Transaction: $CDII Purchase at $0.96 per share of 2676 shares by Officer Wang Yuejian on 2011-09-30.
Insider Transaction: $CDII Purchase at $0.93 per share of 96425 shares by Officer Huang Yuwei on 2011-09-29.
yahoo Fri, Sep 30, 2011, 04:47 PM EST
Tell me something big is not about to happen with >>> $CDII <<<
Insider Transaction: $CDII Purchase at $0.86 per share of 20000 shares by Director Shen Philip Y on 2011-09-22.
yahoo Thu, Sep 22, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.90 per share of 20000 shares by Director Steiner Sheldon on 2011-09-21.
yahoo Thu, Sep 22, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.85 per share of 14000 shares by Director Wasserman Adam on 2011-09-23.
yahoo Fri, Sep 23, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.87 per share of 150000 shares by Officer Wang Yuejian on 2011-09-22.
yahoo Fri, Sep 23, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.85 per share of 14000 shares by Director Wasserman Adam on 2011-09-23.
yahoo Fri, Sep 23, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.86 per share of 15000 shares by Officer Wang Andrew X. on 2011-09-26.
yahoo Mon, Sep 26, 2011, 04:45 PM EST
Insider Transaction: $CDII Purchase at $0.96 per share of 95200 shares by Director Tung Kong on 2011-09-29.
yahoo Thu, Sep 29, 2011, 04:44 PM EST
Insider Transaction: $CDII Purchase at $0.86 per share of 53575 shares by Officer Huang Yuwei on 2011-09-28.
yahoo Thu, Sep 29, 2011, 04:44 PM EST
Insider Transaction: $CDII Purchase at $0.96 per share of 2676 shares by Officer Wang Yuejian on 2011-09-30.
Insider Transaction: $CDII Purchase at $0.93 per share of 96425 shares by Officer Huang Yuwei on 2011-09-29.
yahoo Fri, Sep 30, 2011, 04:47 PM EST
Long $CDII .93 Tangible B/V 1.93 Cash per share .75 Been watching this one for a while.Its starting to get noticed.
$CHII smart traders agree something brewing in China's metal's markets.
$CDII is my buy going into tommorow
Check it out!
There are very few short sellers of Rexahn Pharmaceuticals Inc (AMEX:RNN) to hold it back from making another spike upwards. Brean Murray research house has a $3 target on the stock. What I like is that insiders are 12.8% of the stock and are vested in its performance.
Insiders buying $RNN as of the last 30 days
I following the $
$RNN on the watchlist
Recovered nice on friday
Looking for more upside
WTF is going on $RNN?
Folks, look at the recovery in $RNN
$RNN RIPPING BACK!!.........WOW
$RNN breakout!!!! off lows!
[color=red][/color]$RNN is bouncing of lows
$RNN AT ALL TIME LOWS-MIGHT BE A BUY
When is the C.C?
No,I have no position in Brav but I will forever keep my eye on this company because it does have potential.
Just wish it was not a pink.
Anyway don't sell....please i'll get the memo...lol
Congrats to my old friends on the Brav board
Missed the recent $price action
Still waiting for Brav to move to a better exchange
Not easy,however I hope Mr.Alex is still working on it.
Anybody catch the buying in $YRCW after hours?
I guess good news
Lot's of rumors floating around China about the steel company $CPSL
Look the hell' out for $CPSL tommorow
That's all i'm saying
I'm not a college kid either....lol
Can anybody please help me find a program that I can download that tracks live high volume stocks/rumors of buyout stocks etc.
Brokerage alerts suck.
If so all stocks not just pennyland
Thank you
I would suggest taking a position in $YRCW after hours.
Do your own D.D
$YRCW should be really interesting...lol
NOTE WORTHY: Look at the chart on $FEED
i like $YRCW to out perform right now,its at the 52 lows
i like $YRCW to out perform right now,its at the 52 lows
We shall see
Note worthy: someone just bot 7,500.000 shares of $YRCW in on block!= half million $
Not retail nor day traders
Note worthy: Someone just bought 7,500,000 shares after hours
$YRCW-COULD RUN
$YRCW
Pot is boiling!
Long yrcw
$ANX
Type A meeting with FDA has been requested. This meeting is to discuss the complete response letter regarding the Company's New Drug Application (NDA) for Exelbine. The Company will present information that it believes demonstrates the authenticity of study drugs used in the pivotal study. Should the Company be successful in its ability to demonstrate the authenticity of study drugs, we believe this will serve as a significant catalyst to the share price. Should FDA require the Company to conduct an additional bioequivalence study we also would view this as a catalyst as FDA has not rejected Exelbine but instead requires further validation. Should the Company discontinue Exelbine clinical trials and look to partner or sell Exelbine, we would view this to be a catalyst as no additional funding would be required for further Exelbine development. We believe there could be a number of interested suitors interested in Exelbine as it is a late stage clinical compound with possibly minimal funding required to obtain approval. In summary, there is no losing situation for the Company in regards to Exelbine in our view.
Exelbine, if approved, could entirely displace Navelbine due its
ANX is developing a study protocol for submission to FDA and intends to continue discussions with FDA regarding requirements for regulatory approval of ANX-514. Should the Company receive approval from the FDA on their study protocol we believe that would serve as a significant catalyst as FDA would be essentially agreeing with the Company’s protocol, thus providing a blueprint for approval.
The Company plans to meet with the FDA to reach agreement on a Phase 3 clinical trial protocol before the end of this year. Considering the Company has a significant amount of data on ANX-188 already, we doubt a significant expenditure will be required to get ANX-188 through the clinic and possibly approved.
All from the Vista Report.